Tango Therapeutics, Inc. cotiza a 23.81 USD y tiene una capitalización bursátil de $4.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinica…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.32 | $-0.29 |
| Estimado | $-0.35 | $-0.32 | $-0.31 | $-0.33 |
| Sorpresa | — | — | -3.2% | +12.1% |
| Métrica | TNGX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -178.4% | -38.6% | -139.8% |
| Net Margin | -162.8% | -33.6% | -129.3% |
| FCF Margin | -224.3% | -13.9% | -210.4% |
| ROE | -29.4% | -40.4% | +11.0% |
| ROA | -25.5% | -32.0% | +6.5% |
| Current Ratio | 16.32 | 2.84 | +13.48 |
| Debt / Equity | — | 0.28 | — |